DENTSPLY SIRONA (NASDAQ:XRAY) Announces Earnings Results, Beats Estimates By $0.17 EPS

DENTSPLY SIRONA (NASDAQ:XRAY) released its earnings results on Thursday. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.17, FiscalAI reports. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $898.00 million during the quarter, compared to analyst estimates of $889.93 million. During the same period last year, the business posted $0.52 earnings per share. DENTSPLY SIRONA’s revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA updated its FY 2026 guidance to 1.400-1.500 EPS.

Here are the key takeaways from DENTSPLY SIRONA’s conference call:

• Q2 revenue declined: Sales fell 4.1% as reported, or 6.3% on a constant-currency basis, with weakness in CAD/CAM, dental consumables, implants and SureSmile. Adjusted EPS was flat at $0.52, while adjusted EBITDA margins were roughly unchanged only after a $44 million tariff refund.
• DENTSPLY SIRONA maintained its 2026 outlook for revenue of $3.5 billion–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff-related effects. Management expects Q3 revenue and earnings to decline sequentially because of seasonality and planned investments.
• The company said the U.S. recovery remains its top priority, but commercial-force training and dealer expansion are expected to have a larger impact in 2027 rather than this year. Management also acknowledged that the U.S. is currently lagging competitors in implants and that SureSmile remains pressured.
• Management reported progress on its 24-month Return-to-Growth plan, including expanded dealer partnerships, clinical education, sales-force certification and increased R&D investment, with improvements expected to become more visible in Q4. DS Core adoption and double-digit APAC milling-system growth were cited as encouraging signs.
• Wellspect remained a bright spot, with revenue up 7.1% on continued new-product sales and geographic expansion. Operating cash flow rose to $99 million from $48 million, and the company repurchased 1.3 million shares while continuing to prioritize debt reduction.

DENTSPLY SIRONA Stock Performance

Shares of XRAY traded down $0.61 during midday trading on Thursday, reaching $13.17. 5,502,740 shares of the stock were exchanged, compared to its average volume of 5,072,347. DENTSPLY SIRONA has a twelve month low of $9.40 and a twelve month high of $14.86. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of -4.18, a PEG ratio of 1.64 and a beta of 0.85. The business’s 50-day moving average price is $11.74 and its 200 day moving average price is $11.89.

Analysts Set New Price Targets

XRAY has been the topic of several recent analyst reports. Piper Sandler increased their target price on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Wednesday, July 29th. Mizuho decreased their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Monday. BMO Capital Markets began coverage on DENTSPLY SIRONA in a report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price objective on the stock. Finally, UBS Group cut their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus price target of $13.46.

Insiders Place Their Bets

In other DENTSPLY SIRONA news, Director Brian T. Gladden purchased 9,985 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the transaction, the director directly owned 61,849 shares in the company, valued at $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Michael J. Barber purchased 15,175 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $9.88 per share, with a total value of $149,929.00. Following the purchase, the director owned 55,943 shares in the company, valued at $552,716.84. This trade represents a 37.22% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 35,160 shares of company stock valued at $351,179 over the last quarter. Company insiders own 0.46% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Goldman Sachs Group Inc. lifted its position in DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the period. Empowered Funds LLC grew its stake in shares of DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares during the period. Finally, Focus Partners Wealth increased its holdings in shares of DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.